Drug intelligence / Profile preview

adebrelimab + apatinib + chemotherapy

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Adebrelimab + apatinib + chemotherapy is a combination therapeutic regimen being investigated for the treatment of biliary tract cancers, specifically intrahepatic cholangiocarcinoma (ICC). The regimen consists of adebrelimab, a humanized monoclonal antibody targeting programmed cell death 1 ligand 1 (PD-L1); apatinib (also known as rivoceranib), a small molecule tyrosine kinase inhibitor highly selective for vascular endothelial growth factor receptor 2 (VEGFR2); and a chemotherapy backbone such as GEMOX (gemcitabine and oxaliplatin) or gemcitabine and cisplatin. This combination aims to leverage the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy. It is currently being evaluated in Phase 2 clinical trials sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as both a neoadjuvant/adjuvant (perioperative) treatment for resectable ICC and as a first-line treatment for unresectable ICC.

Brand names: AiRuiKaAiTan
Other names: rivoceranibSHR1316SHR-1316SHR 1316YN968D1YN-968D1YN 968D1

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on adebrelimab + apatinib + chemotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + apatinib + chemotherapy.

Explore the full profile